# Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04855656/  
OnCo record `nct04855656` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Lunresertib run by Debiopharm International SA, now recruiting.

## Summary

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT04855656 by Debiopharm International SA, with 464 participants planned, started 2021-04-30. Conditions recorded: Advanced Solid Tumor. Interventions recorded: Lunresertib, RP-3500 and Zedoresertib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04855656
- Phase: 1
- Setting: Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- Sponsor: Debiopharm International SA
- Enrolled: 464

## Sources

- ClinicalTrials.gov NCT04855656: https://clinicaltrials.gov/study/NCT04855656

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Lunresertib](https://onco.cc/drugs/lunresertib/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/), [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04855656.json